SF 552 (LSB 1939SV (2) 91)

SENATE FILE 552

BY  COMMITTEE ON HEALTH AND HUMAN SERVICES

(SUCCESSOR TO SSB 1138)

A BILL FOR

An Act relating to a review of anti-obesity medications by the department of health and human services and the department of administrative services for purposes of the medical assistance program and health insurance plans for state employees.
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

    Section 1.  ANTI-OBESITY MEDICATION REVIEW AND REPORT.  For purposes of the medical assistance program under chapter 249A and health insurance plans for state employees established pursuant to chapter 509A, the department of health and human services and the department of administrative services shall review anti-obesity medications, including GLP-1 agonists, for effectiveness relating to weight loss, the impact on comorbidities, the potential for cost savings due to deferred medical procedures and reduced medications related to comorbidity, recommended eligibility requirements, any short-term and long-term costs associated with coverage, and any other criteria the departments deem relevant. The department of health and human services and the department of administrative services shall submit a report to the general assembly by January 5, 2026, with the departments’ findings, proposed eligibility requirements, and any short-term and long-term costs associated with coverage.
EXPLANATION
The inclusion of this explanation does not constitute agreement with
the explanation’s substance by the members of the general assembly.
   This bill relates to the department of health and human services (HHS) and the department of administrative services (DAS) review of anti-obesity medication for purposes of the medical assistance program and health insurance plans for state employees established pursuant to Code chapter 509A.
   The bill requires HHS and DAS to review anti-obesity medications, including GLP-1 agonists, for effectiveness, comorbidities, cost savings, eligibility requirements, and short-term and long-term costs associated with coverage. HHS and DAS shall submit a report to the general assembly by January 5, 2026, containing HHS’s and DAS’s findings, proposed eligibility requirements, and any short-term and long-term costs associated with coverage.